- Hemophilia B drugs are essential treatments for managing bleeding episodes in patients with a deficiency of clotting Factor IX, helping prevent severe complications and improving quality of life
- The market demand is significantly driven by increasing disease prevalence, advancements in gene therapy and recombinant products, and improved diagnostic capabilities
- North America is expected to dominate the hemophilia B drugs market with a market share of 44.5%, due to advanced healthcare infrastructure, high adoption of innovative treatments, and a strong presence of key pharmaceutical players
- Asia-Pacific is expected to be the fastest growing region in the Hemophilia B drug market with a market share of 19.5%, during the forecast period due to rapid expansion in healthcare infrastructure, increasing awareness about genetic disorders, and rising diagnosis rates
- The recombinant coagulation factor concentrates segment is expected to dominate the market with a market share of 58.7% due to its superior safety profile, as it eliminates the risk of blood-borne infections associated with plasma-derived products
